Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT04959448

Study Assessing Long-teRm Outcomes of dupiluMAb (DUPIXENT®) Treatment in Adult Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)

The primary objectives of the study are:

* To longitudinally characterize the long-term effectiveness of DUPIXENT® through assessment of patient-reported symptoms, Health-Related Quality of Life (HRQoL) related to Chronic rhinosinusitis with nasal polyposis (CRSwNP) and other type 2 comorbidities, and their change over-time. * To characterize patients who receive DUPIXENT® for CRSwNP in a real-world setting with respect to their medical history, demographic and disease characteristics, and type 2 comorbidities

The secondary objectives of the study are:

* To characterize real-world utilization of DUPIXENT® for patients with CRSwNP * To collect patient and physician global assessment of disease severity and treatment satisfaction for patients receiving DUPIXENT® for CRSwNP * To collect long-term safety data for patients receiving DUPIXENT® for CRSwNP

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Chronic Rhinosinusitis With Nasal Polyposis

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

ENT Clinic Sinus Center, St. Paul's Hospital, Vancouver, British Columbia, Canada

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Key Inclusion Criteria:

  • All patients who are newly initiated on DUPIXENT® for the treatment of CRSwNP according to the respective prescribing information (Product Label or SmPC)
  • Willing and able to comply with clinic visits and study-related procedures as per protocol
  • Provide informed consent signed by study patient or legally acceptable representative
  • Able to understand and complete study-related questionnaires as per protocol

Key Exclusion Criteria:

  • Patients who have a contraindication to DUPIXENT® according to the country-specific prescribing information
  • Any previous treatment with DUPIXENT® for any condition
  • Any condition that, in the opinion of the investigator, may interfere with the patient's ability to participate in the study per protocol
  • Participation in an ongoing interventional or observational study that might, in the treating physician's opinion, influence the assessments for the current study per protocol

Treatment and study plan

Dupixent®

Drug

No investigational agents will be provided. All treatments will be prescribed at the discretion of the study physician and other healthcare providers.

Other names: dupilumab, REGN668, SAR231893

Primary outcomes

  1. Baseline Patient Characteristics

    Time frame: Baseline up to 3 years

    Demographics includes but is not limited to gender, age, ethnicity, height, weight, BMI, education, current employment status, physician information.

  2. Baseline Disease Characteristics

    Time frame: Baseline up to 3 years

    Medical History includes but is not limited to history of CRSwNP, comorbid conditions, age at CRSwNP diagnosis, and baseline measurements of effectiveness variables.

Secondary outcomes

  1. DUPIXENT® Treatment Characteristics

    Time frame: Baseline up to 3 years

    Including but not limited to: usage, dosage, adherence, interruption, place (home or clinic) and frequency of administration

  2. CRSwNP Treatment Characteristics

    Time frame: Baseline up to 3 years

    Including but not limited to: usage, dosage, adherence, duration and frequency

  3. Incidence and severity of adverse events (AEs)

    Time frame: Baseline up to 3 years

  4. Participant Assessment: Total symptom score (TSS), including sub-scores (nasal congestion [NC] and loss of smell [LOS])

    Time frame: Baseline up to 3 years

    The TSS is a composite score (ranging between 0 and 9) and consisting of the sum of the following symptoms assessed daily: nasal congestion/obstruction, decreased/loss of sense of smell, rhinorrhea (average of anterior/posterior nasal discharge). Higher scores indicate greater symptom burden.

  5. Physician Assessment: Change in University of Pennsylvania Smell Identification Test (UPSIT) score

    Time frame: Baseline up to 3 years

    The UPSIT (UPSIT 40-odorant test) is a rapid and easy-to-administer method to quantitatively assess human olfactory function.

  6. Physician Assessment: CT-Lund-Mackay Score

    Time frame: Baseline up to 3 years

    The LMK system is scoring based on CT imaging of the sinuses with points given for degree of opacification:

    0 = no opacification, 1 = partial opacification, 2 = total opacification. These points are then applied to the maxillary, anterior ethmoid, posterior ethmoid, sphenoid, frontal sinus on each side. The ostiomeatal complex is graded as 0 = not occluded, or 2 = occluded. The sum of these derives a maximum score of 12 per side and 24 in total.

  7. Physician Assessment: Nasal Peak Inspiratory Flow (PNIF)

    Time frame: Baseline up to 3 years

    Nasal peak inspiratory flow (NPIF) is a measure of the air flow through both nasal cavities during forced inspiration expressed in liters per minute.

  8. Physician Assessment: - Forced Expiratory Volume in 1 second (FEV1)

    Time frame: Baseline up to 3 years

    Forced Expiratory Volume in 1 second (FEV1) is the amount of air which can be forcibly exhaled in the first second of a forced exhalation

  9. Physician Assessment: Fractional exhaled Nitric Oxide (FeNO)

    Time frame: Baseline up to 3 Years

    FeNO (Fractional exhaled Nitric Oxiide) is analyzed using a respiratory flow rate of 50 mL/second and reported in ppb.

  10. Participant Assessment: Asthma Control Questionnaire, 6-item (ACQ-6)

    Time frame: Baseline up to 3 Years

    The ACQ-6 assesses asthma control with scores ranging from 0 (fully controlled; 6=severely uncontrolled).

  11. Participant Assessment: Mini Asthma Quality of Life Questionnaire (MiniAQLQ)

    Time frame: Baseline up to 3 Years

    The MiniAQLQ is assesses the impact of asthma on health-related quality of life with scores ranging from 1 (maximum impairment) to 7 (no impairment).

  12. Participant Assessment: Allergic Rhinitis (AR) using AR Visual Analog Scale (VAS)

    Time frame: Baseline up to 3 Years

    The AR-VAS assesses severity of rhinosinusitis symptoms on a 0 (not troublesome) to 10 (worst thinkable troublesome) scale.

  13. Participant Assessment: Mini Rhinoconjunctivitis Quality of Life Questionnaire (MiniRQLQ)

    Time frame: Baseline up to 3 Years

    The MiniRQLQ is an abbreviated version of the RQLQ(S)+12 which assesses health-related quality of life associated with perennial or seasonal allergic rhinitis with scores ranging from 0 (not troubled) to 6 (extremely troubled).

  14. Participant Assessment: Sino-Nasal Outcome Test (SNOT-22)

    Time frame: Baseline up to 3 Years

    The SNOT-22 assesses the impact of chronic rhinosinusitis on health-related quality of life with scores ranging from 0 to 110; lower scores representing better health related quality of life.

  15. Participant Assessment: Patient Oriented Eczema Measure (POEM)

    Time frame: Baseline up to 3 Years

    The POEM assesses symptoms of dryness, itching, flaking, cracking, sleep loss, bleeding, and weeping with scores ranging from 0 to 28; higher scores indicate greater symptom burden.

  16. Participant Assessment: Work Productivity and Activity Impairment Questionnaire for asthma (WPAI-CRSwNP)

    Time frame: Baseline up to 3 Years

    The WPAI-CRSwNP measures impairments in work and activities associated with CRSwNP. Scores are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.

  17. Physician Assessment: Changes of Healthcare Utilization

    Time frame: Baseline up to 3 years

    Resource use collected from medical, hospital, and pharmacy records

  18. Participant Assessment: Short Form 12

    Time frame: Baseline up to 3 years

    The SF-12 assesses physical functioning, social functioning, role limitations due to physical problems, role limitations due to emotional problems, mental health, energy/vitality, pain, and general health perception with scores ranging from 0 to 100; lower scores represent greater quality of life impairment.

  19. Participant Assessment: European Quality of Life 5-Dimensions, 5-Level Questionnaire (EQ-5D-5L)

    Time frame: Baseline up to 3 years

    The EQ 5D-5L descriptive system comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression and the EQ-VAS records the respondent's self rated health on a scale of 0 (worst imaginable health state) to 100 (best imaginable health state).

  20. Participant Assessment: Global Impression for Symptom Severity, Treatment Satisfaction (Global Patient Assessment)

    Time frame: Baseline up to 3 years

    The Global Patient Assessment is a 2-component questionnaire on symptom severity over the past week and the patient's overall satisfaction with their CRSwNP treatment.

  21. Physician Assessment: Global Impression for Disease Severity (Global Physician Assessment)

    Time frame: Baseline up to 3 years

    The Global Physician Assessment is a 1-item question asking physicians to rate the severity of their patient's CRSwNP.

Sponsors and collaborators

Lead sponsor

Regeneron Pharmaceuticals

Industry

Collaborators

  • Sanofi

Registry information

Official study title

Assessing Long-Term Outcomes of DUPIXENT® Treatment in Patients With Chronic Rhinosinusitis With Nasal Polyposis (AROMA)

Acronym: AROMA

Important dates

Study start
2021
Primary completion
2027
Study completion
2027
First posted
Jul 13, 2021
Registry last updated
Jul 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.